Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen

Bone Marrow Transplantation

Volumn 36, Issue 5, 2005, Pages 389-396

  Dawson, M A ^a   Schwarer, A P ^a   Muirhead, J L ^a   Bailey, M J ^b   Bollard, G M ^a   Spencer, A ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Autologous transplant; Heavily pretreated; PBSC collection; Remobilization; Stem cell factor

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CD34 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR; SERUM ALBUMIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ALGORITHM; AMYLOIDOSIS; ARTICLE; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HODGKIN DISEASE; HUMAN; LEUKAPHERESIS; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PERFORMANCE; PERIPHERAL BLOOD STEM CELL; PREDICTION; PRIORITY JOURNAL; PRURITUS; SKIN MANIFESTATION; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; TREATMENT FAILURE;

ADULT; AGED; ANTIGENS, CD34; CELL SEPARATION; DRUG EVALUATION; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL FACTOR; TREATMENT FAILURE;

EID: 30944441660     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705069     Document Type: Article

References (39)

1. Gratwohl A, Baldomero H, Passweg J et al. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia 2003; 17: 941-959.
2. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998; 92: 1073-1090.
3. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
4. Drake M, Ranaghan L, Morris TC et al. Analysis of the effect of prior therapy on progenitor cell yield: Use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745-749.
5. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
6. Moskowitz CH, Glassman JR, Wuest D et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-316.
7. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collections. Br J Haematol 1996; 93: 142-145.
8. Demirer T, Buckner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
9. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
10. Demirer T, Buckner CD, Bensinger WI. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14: 106-116.
11. Stiff P, Gingrich R, Luger S et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-481.
12. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
13. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345-1364.
14. Bernstein ID, Andrews RG, Zsebo KM. Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin- cells, and the generation of colony-forming cell progeny from CD34+lin- cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 2316-2321.
15. McNiece IK, Langley KE, Zsebo KM. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991; 19: 226-231.
16. To LB, Bashford J, Durrant S et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003; 31: 371-378.
17. Moskowitz CH, Stiff P, Gordon MS et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - results of a phase I/II trial. Blood 1997; 89: 3136-3147.
18. Schwarer AP, Messino NM, Gibson M et al. A randomized trial of leukapheresis volumes, 7 L versus 10 L: An assessment of efficacy and patient tolerance. J Hematother Stem Cell Res 2000; 9: 269-274.
19. Stroncek DF, Clay ME, Smith J et al. Comparison of two blood cell separators in collecting peripheral blood stem cell components. Transfus Med 1997; 7: 95-99.
20. Mehta J, Singhal S, Gordon L et al. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. Bone Marrow Transplant 2002; 29: 563-567.
21. Ford CD, Lehman C, Strupp A, Kelley L. Comparison of CD34+ cell collection efficiency on the COBE Spectra and Fenwal CS-3000 Plus. J Clin Apheresis 2002; 17: 17-20.
22. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
23. Magrath I, Adde M, Shad A et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
24. Lazzarino M, Corso A, Barbarano L et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001; 28: 835-839.
25. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596-602.
26. Linch DC, Smith P, Hancock BW et al. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 2000; 11 (Suppl 1): 87-90.
27. Spencer ASM, Denfridge SF, Enno A. ESHAP and ESHAC are effective as salvage therapy and for stem cell mobilisation in poor risk NHL. Br J Haematol 1998; 102: 238.
28. Da Silva MG, Pimentel P, Carvalhais A et al. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection. Bone Marrow Transplant 2004; 34: 683-691.
29. Azar NVJ, Vantelon J, Hashmanti P et al. Ancestim (r-metHuSCF): mobilization of peripheral blood stem cells(PBSC) in patients with prior unsuccessful mobilization with G-CSF. Experience of 67 cases of compassionate use in France. Blood 2000; 96: 176a.
30. Lapidot T, Petit I. Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973-981.
31. Cottler-Fox MH, Lapidot T, Petit I et al. Stem cell mobilization. Hematology (Am Soc Hematol Educ Program) 2003, 419-437.
32. Ponomaryov T, Peled A, Petit I et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000; 106: 1331-1339.
33. Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
34. Takamatsu Y, Simmons PJ, Moore RJ et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 1998; 92: 3465-3473.
35. Lie AK, Rawling TP, Bayly JL, To LB. Progenitor cell yield in sequential blood stem cell mobilization in the same patients: Insights into chemotherapy dose escalation and combination of haemopoietic growth factor and chemotherapy. Br J Haematol 1996; 95: 39-44.
36. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999; 23 (Suppl. 2): S29-S33.
37. Lie AK, Hui CH, Rawling T et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transplant 1998; 22: 853-857.
38. Boeve S, Strupeck J, Creech S, Stiff PJ. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: Risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997-1003.
39. Liles WC, Rodger E, Broxmeyer HE et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300.